NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000005191

Registered date:06/03/2011

XELOX stop-and-go trial:A phase 2 study of 1st line chemotherapy for unresectable or recurrent colorectal cancer.

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedUnresectable or recurrent colorectal cancer
Date of first enrollment2010/05/01
Target sample size37
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)XELOX therapy 6 courses, followed by XELODA 6 courses, then XELOX

Outcome(s)

Primary OutcomeProgression free survival
Secondary OutcomeResponse rate Time to treatment failure Overall survival Safety plofiles(Rate of Grade 3 neurotoxicity, adverse events)

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum75years-old
GenderMale and Female
Include criteriaFrom 25 to 75 years old, colorectal cancer, PS 0-1, chemotherapy naive, proper organ function, not indicated for bevacizumab for some reasons.
Exclude criteriaDouble cancer, severe allergic history, active infections, severe complications

Related Information

Contact

public contact
Name
Address Japan
Telephone
E-mail
Affiliation Kyushu University Hospital Hematology and Oncology
scientific contact
Name Eishi Baba
Address 3-1-1, Maedashi, Higashi-ku, Fukuokashi Japan
Telephone
E-mail
Affiliation Kyushu University Hospital Hematology and Oncology